Clinical Trial Update: A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of CTX-712 in relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CTX-712

Snippet

Sponsor: Chordia Therapeutics, Inc. | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: RECRUITING